Status Epilepticus: An Update on Pharmacological Management

Abstract

Status epilepticus (SE) is a neurological emergency that requires timely pharmacological therapy to cease seizure activity. The treatment approach varies based on the time and the treatment stage of SE. Benzodiazepines are considered the first-line therapy during the emergent treatment phase of SE. Antiseizure medicines such as phenytoin, valproic acid, and levetiracetam are recommended during the urgent treatment phase. These drugs appear to have a similar safety and efficacy profile, and individualized therapy should be chosen based on patient characteristics. Midazolam, propofol, pentobarbital, and ketamine are continuous intravenous infusions of anesthetic medications utilized in the refractory SE (RSE) period. The most efficacious pharmacotherapeutic treatments for RSE and superrefractory status epilepticus are not clearly defined.

Keywords

status epilepticus - seizure - medication - benzodiazepine - antiseizure - antiepileptic - treatment

Publication History

Article published online:
05 April 2024

• References

• 1 Westover MB, Shafi MM, Bianchi MT. et al. The probability of seizures during EEG monitoring in critically ill adults. Clin Neurophysiol 2015; 126 (03) 463-471
• 2 Fisher RS, van Emde Boas W, Blume W. et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46 (04) 470-472
• 3 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56 (10) 1515-1523
• 4 Scheffer IE, Berkovic S, Capovilla G. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58 (04) 512-521
• 5 Brophy GM, Bell R, Claassen J. et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17 (01) 3-23
• 6 Glauser T, Shinnar S, Gloss D. et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016; 16 (01) 48-61
• 7 Almohaish S, Sandler M, Brophy GM. Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med 2021; 10 (08) 1754
• 8 Silbergleit R, Durkalski V, Lowenstein D. et al; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366 (07) 591-600
• 9 Lorazepam Injection insert. Accessed January 6, 2021 at: https://webcache.googleusercontent.com/search?q=cache:OLkMdcRKnCMJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018140s028lbl.pdf+&cd=2&hl=en&ct=clnk&gl=us
• 10 DIAZEPAM Injection insert. Accessed January 6, 2021 at. https://webcache.googleusercontent.com/search?q=cache:GOD94rHmAFQJ:https://dailymed.nlm.nih.gov/dailymed/getFile.cfm%3Fsetid%3D7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f%26type%3Dpdf+&cd=1&hl=en&ct=clnk&gl=us
• 11 Midazolam injection insert. Accessed January 6, 2021 at. https://webcache.googleusercontent.com/search?q=cache:z54yylc3GggJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208878Orig1s000lbl.pdf+&cd=1&hl=en&ct=clnk&gl=us
• 12 Sathe AG, Underwood E, Coles LD. et al. Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. Epilepsia 2021; 62 (03) 795-806
• 13 Rao SK, Mahulikar A, Ibrahim M, Shah A, Seraji-Bozorgzad N, Mohamed W. Inadequate benzodiazepine dosing may result in progression to refractory and non-convulsive status epilepticus. Epileptic Disord 2018; 20 (04) 265-269
• 14 Alvarez V, Lee JW, Drislane FW. et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison. Epilepsia 2015; 56 (08) 1275-1285
• 15 Guterman EL, Sanford JK, Betjemann JP. et al. Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticus. Neurology 2020; 95 (24) e3203-e3212
• 16 Jain P, Sharma S, Dua T, Barbui C, Das RR, Aneja S. Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis. Epilepsy Res 2016; 122: 47-55
• 17 Holsti M, Dudley N, Schunk J. et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med 2010; 164 (08) 747-753
• 18 Inokuchi R, Ohashi-Fukuda N, Nakamura K. et al. Comparison of intranasal and intravenous diazepam on status epilepticus in stroke patients: a retrospective cohort study. Medicine (Baltimore) 2015; 94 (07) e555
• 19 Midazolam spray insert. Accessed January 6, 2021 at: https://webcache.googleusercontent.com/search?q=cache:euZ4ObhBXBUJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf+&cd=3&hl=en&ct=clnk&gl=us
• 20 Diazepam spray insert. Accessed January 6, 2021 at: https://webcache.googleusercontent.com/search?q=cache:miXzrZfiKT0J:https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf+&cd=1&hl=en&ct=clnk&gl=us
• 21 Kapur J, Elm J, Chamberlain JM. et al; NETT and PECARN Investigators. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 2019; 381 (22) 2103-2113
• 22 Morgan O, Medenwald B. Safety and tolerability of rapid administration undiluted levetiracetam. Neurocrit Care 2020; 32 (01) 131-134
• 23 Adams T, Greathouse K. Evaluation of time to administration, benzodiazepine use, and safety of intravenous push levetiracetam in a neuro-spine intensive care unit. Neurocrit Care 2021; 35 (03) 789-793
• 24 Husain AM, Lee JW, Kolls BJ. et al; Critical Care EEG Monitoring Research Consortium. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol 2018; 83 (06) 1174-1185
• 25 Panda PK, Panda P, Dawman L, Sharawat IK. Efficacy of lacosamide and phenytoin in status epilepticus: a systematic review. Acta Neurol Scand 2021; 144 (04) 366-374
• 26 Strein M, Holton-Burke JP, Stilianoudakis S, Moses C, Almohaish S, Brophy GM. Levetiracetam-associated behavioral adverse events in neurocritical care patients. Pharmacotherapy 2023; 43 (02) 122-128
• 27 Aicua-Rapun I, André P, Rossetti AO, Decosterd LA, Buclin T, Novy J. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res 2019; 149: 88-91
• 28 Santamarina E, Parejo Carbonell B, Sala J. et al. Use of intravenous brivaracetam in status epilepticus: a multicenter registry. Epilepsia 2019; 60 (08) 1593-1601
• 29 Brivaracetam insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:O5zYTbEwGWEJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205836s005,205837s004,205838s003lbl.pdf&cd=1&hl=en&ct=clnk&gl=us
• 30 Phenytoin Insert. Accessed February 6, 2023 at: https://labeling.pfizer.com/showlabeling.aspx?id=546
• 31 Lacosamide insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:Zi61N9IOktIJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022253s039,022254s030,022255s022lbl.pdf&cd=2&hl=en&ct=clnk&gl=us
• 32 Levetiracetam insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:jzxcGG3APCUJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s078s080%252C021505s021s024lbl.pdf&cd=2&hl=en&ct=clnk&gl=us
• 33 Depakene (valproic acid) insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:pZrfTmaOPNEJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018081s046_18082s031lbl.pdf&cd=1&hl=en&ct=clnk&gl=us
• 34 Davidson KE, Newell J, Alsherbini K, Krushinski J, Jones GM. Safety and efficiency of intravenous push lacosamide administration. Neurocrit Care 2018; 29 (03) 491-495
• 35 Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009; 5: 757-766
• 36 Haller JT, Bonnin S, Radosevich J. Rapid administration of undiluted intravenous levetiracetam. Epilepsia 2021; 62 (08) 1865-1870
• 37 Jense A, Douville A, Weiss A. The safety of rapid infusion levetiracetam: a systematic review. Pharmacotherapy 2022; 42 (06) 495-503
• 38 Limdi NA, Knowlton RK, Cofield SS. et al. Safety of rapid intravenous loading of valproate. Epilepsia 2007; 48 (03) 478-483
• 39 Guterman EL, Betjemann JP, Aimetti A. et al. Association between treatment progression, disease refractoriness, and burden of illness among hospitalized patients with status epilepticus. JAMA Neurol 2021; 78 (05) 588-595
• 40 Rai S, Drislane FW. Treatment of refractory and super-refractory status epilepticus. Neurotherapeutics 2018; 15 (03) 697-712
• 41 Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43 (02) 146-153
• 42 Pugin D, Foreman B, De Marchis GM. et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. Crit Care 2014; 18 (03) R103
• 43 Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011; 14 (01) 4-10
• 44 Newey CR, Wisco D, Nattanmai P, Sarwal A. Observed medical and surgical complications of prolonged barbiturate coma for refractory status epilepticus. Ther Adv Drug Saf 2016; 7 (05) 195-203
• 45 Corbett SM, Montoya ID, Moore FA. Propofol-related infusion syndrome in intensive care patients. Pharmacotherapy 2008; 28 (02) 250-258
• 46 Zhang Q, Yu Y, Lu Y, Yue H. Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus. BMC Neurol 2019; 19 (01) 55
• 47 Rosati A, De Masi S, Guerrini R. Ketamine for refractory status epilepticus: a systematic review. CNS Drugs 2018; 32 (11) 997-1009
• 48 Kimmons LA, Alzayadneh M, Metter EJ, Alsherbini K. Safety and Efficacy of Ketamine Without Intubation in the Management of Refractory Seizures: A Case Series. Neurocrit Care 2024; 40 (02) 689-697
• 49 Willems LM, Bauer S, Jahnke K, Voss M, Rosenow F, Strzelczyk A. Therapeutic options for patients with refractory status epilepticus in palliative settings or with a limitation of life-sustaining therapies: a systematic review. CNS Drugs 2020; 34 (08) 801-826
• 50 Strzelczyk A, Knake S, Kälviäinen R. et al. Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain. Acta Neurol Scand 2019; 139 (04) 369-376
• 51 Farrokh S, Bon J, Erdman M, Tesoro E. Use of newer anticonvulsants for the treatment of status epilepticus. Pharmacotherapy 2019; 39 (03) 297-316
• 52 Zonisamide insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:BMC8d71Mh38J:https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020789s019lbl.pdf&cd=1&hl=en&ct=clnk&gl=us
• 53 Hubert K, Knake S, Bauer S, Voss M, Rosenow F, Strzelczyk A. Treatment of status epilepticus with zonisamide: a multicenter cohort study of 34 patients and review of literature. Epilepsy Behav 2020; 109: 107139
• 54 Legriel S, Oddo M, Brophy GM. What's new in refractory status epilepticus?. Intensive Care Med 2017; 43 (04) 543-546
• 55 Vaitkevicius H, Ramsay RE, Swisher CB, Husain AM, Aimetti A, Gasior M. Intravenous ganaxolone for the treatment of refractory status epilepticus: results from an open-label, dose-finding, phase 2 trial. Epilepsia 2022; 63 (09) 2381-2391
• 56 Rosenthal ES, Claassen J, Wainwright MS. et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol 2017; 82 (03) 342-352
• 57 Onfi® (Clobazam) insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:sDdS5BkGp1AJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203993s005lbl.pdf&cd=1&hl=en&ct=clnk&gl=us
• 58 Perampanel insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:fWkw7VJWDi4J:https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf&cd=2&hl=en&ct=clnk&gl=us
• 59 PHENOBARBITAL insert. Accessed February 6, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215910s000lbl.pdf
• 60 Topiramate insert. Accessed February 6, 2023 at: https://webcache.googleusercontent.com/search?q=cache:sExXpwIHq_sJ:https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf&cd=1&hl=en&ct=clnk&gl=us
• 61 Almohaish S, Cook AM, Brophy GM, Rhoney DH. Personalized antiseizure medication therapy in critically ill adult patients. Pharmacotherapy 2023; 43 (11) 1166-1181